Prolonged administration of IGF peptides enhances growth of gastrointestinal tissues in normal rats

Steeb, C. B.; Trahair, J. F.; Tomas, F. M.; Read, Leanna C.

doi:10.1152/ajpgi.1994.266.6.g1090

Cited by 59 publications

(73 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It stimulates gut epithelial cell proliferation (Chen et al 1991, Steeb et al 1994 and increases gut weight in rats after dexamethasone treatment or partial gut resection . It may also accelerate maturation of gut permeability (McRoberts & Riley 1992) and brush border enzyme maturation in neonatal rats (Young et al 1990, Ma & Xu 1997.…”

Section: Discussionmentioning

confidence: 99%

Enteral IGF-I enhances fetal growth and gastrointestinal development in oesophageal ligated fetal sheep

Kimble¹,

Breier²,

Gluckman³

et al. 1999

Journal of Endocrinology

View full text Add to dashboard Cite

Infants with upper gut atresia often have impaired intrauterine growth and gut function. IGF-I is important in fetal growth and is contained in amniotic fluid. We therefore wanted to test the hypothesis that IGF-I infused into fetal gut would reverse the effects of an upper gut obstruction on gut structure and growth in fetal sheep.At 90 days gestation fetuses (n=6 per group) underwent oesophageal ligation, followed by continuous infusion of IGF-I (1-8 µg/day) or saline into the gut beyond the ligation until 137 days. Controls underwent sham ligation only. Oesophageal ligation tended to reduce fetal body and organ weights. IGF-I treatment prevented this reduction and increased body length and spleen weight above those of controls. The decrease in bowel wall thickness induced by oesophageal ligation was also prevented by IGF-I treatment. Amniotic fluid IGF-I concentrations did not change over gestation and were higher in the IGF-I treated group. No change in fetal plasma IGF-I concentrations were detectable. We conclude that enterally administered IGF-I may enhance fetal growth and gut development in utero and that IGF-I in amniotic fluid may play a physiological role in gut development in the fetus.

show abstract

Section: Discussionmentioning

confidence: 99%

Enteral IGF-I enhances fetal growth and gastrointestinal development in oesophageal ligated fetal sheep

Kimble¹,

Breier²,

Gluckman³

et al. 1999

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Intestinal proliferative response to human recombinant IGF-I at doses much higher than that in colostrum has been observed in experiments. Using long R3 IGF-I (LR3IGF-I), an IGF-I analogue with greater biological potency than IGF-I thought to result from its different pharmacokinetic characteristics, Steeb et al [203,204] have demonstrated the remarkable intestinal proliferative response to both a 14-day course and a 3-day course infusion in adult rats. In normal adult rats, a 14-day infusion of LR3IGF-I at 278 Ìg/day (approximately 2.42 mg/kg/day) resulted in an increase in total gut weight by 43%, small intestine weight by 47%, small intestine length by 13%, an increase in crypt depth and villus height with an associated 33% increase in crypt cell population, 34% increase in cells per villus column, and 20% in villus cell density [201].…”

Section: Protein Undernutrition and Nutritionally Regulated Hormonal mentioning

confidence: 99%

Nutritionally Regulated Hormonal Factors in Prolonged Postnatal Growth Retardation and Its Associated Adverse Neurodevelopmental Outcome in Extreme Prematurity

Yeung¹,

Smyth²

2003

Neonatology

View full text Add to dashboard Cite

Recent published data show that at hospital discharge, most infants born at <30 weeks of gestation would not achieve the median birth weight of the reference fetus at the same postconceptional age, and many would be less than the 10th centile. Estimating from the current recommendations of calorie and protein intakes, these infants accrue large deficits in intakes of protein and calorie during the first weeks of life. Postnatal growth retardation over a prolonged period of time is related to neurodevelopmental delays. While a total energy intake of 120 kcal/kg/day has generally been considered adequate, protein requirement in low gestation infants remains a matter for debate. Increasing the dietary protein:calorie ratio has previously been proposed as a strategy to enhance growth and to achieve a body composition similar to that of the reference fetus. Previous study data reveal that serum insulin-like growth factor I (IGF-I) concentration is positively correlated with protein intake, and nitrogen retention, in turn, is positively correlated with serum IGF-I concentration. Remarkably, elevated serum growth hormone but low serum IGF-I concentrations have been reported in low gestation infants and in infants with intrauterine growth retardation, suggesting IGF-I being a nutritionally regulated hormonal factor in the postnatal growth retardation. As neurodevelopment in extreme prematurity is likely affected by multiple factors, we hypothesize that a combined strategy of the previously proposed hormonal supplement with hydrocortisone and tri-iodothyronine together with increased dietary protein intake (progressively increasing from 1.5 g/kg/day intravenously administered amino acids immediately after birth, then 3.6 g/100 kcal at ≈125 kcal/kg/day when enterally fed till the infant reaches a body weight of ≧1.8 kg and at ≧50th centile weight of the reference fetus at the same postconceptional age) would likely be synergistic and more effective in improving neurodevelopmental outcome.

show abstract

“…In this experiment we did not investigate the effect of surgery or IGF-I on the intestinal mucosa. Following resection of the small intestine or colon the administration of IGF-I can produce changes in the wall of the gut, so it was interesting to investigate the effects of major surgery and administration of IGF-I on circulating gastrointestinal hormones and growth factors (Adrian et al 1987, Vanderhoof et al 1992, Steeb et al 1994, Wirén et al 1995, Zhang et al 1995, Inaba et al 1997, Shimoda et al 1997. It has been reported that both enteroglucagon and PYY increase massively following small bowel resection (Armstrong et al 1991).…”

Section: Figure 1 Serum Concentrations Of Igf-i In Patients Given Igfmentioning

confidence: 99%

“…This effect is likely to be mediated by IGF-I, since an increase in IGF-I mRNA was found in the intestinal mucosa in GH-transgenic mice (Ulshen et al 1993). Long-term administration of IGF-I has a positive effect on the growth of the gastrointestinal tract (Steeb et al 1994). This effect is also seen after intestinal resection and transplantation (Vanderhoof et al 1992, Zhang et al 1995.…”

Section: Introductionmentioning

confidence: 99%

Gastrointestinal growth factors and pancreatic islet hormones during postoperative IGF-I supplementation in man

Leinsköld

Adrian²,

Arnelo³

et al. 2000

Journal of Endocrinology

View full text Add to dashboard Cite

Insulin-like growth factor-I (IGF-I) has been demonstrated to exert a nitrogen sparing effect, both experimentally and in patients after abdominal surgery. IGF-I is a major mediator for the anabolic effects of growth hormone (GH). Whether elevated circulating IGF-I levels are the sole mediator of the anabolic effects following GH has not been clarified. IGF-I influences glucose metabolism, both through its own specific receptor and by activating the insulin receptor, and has also been proposed to influence pancreatic islet secretion directly. In the present study, the postoperative effects of IGF-I on plasma levels of other gastrointestinal and pancreatic islet hormones and growth factors were measured in patients after abdominal surgery.Fifteen patients who were candidates for large bowel resection were randomly divided into two groups: IGF-Itreated (n=8) and placebo-treated (n=7). The IGF-I group received daily two s.c. injections of human recombinant IGF-I (80 µg/kg body weight) for five days, beginning on the morning of the first postoperative day. The other group received placebo injections. Fasting plasma levels of gastrointestinal growth factors (epidermal growth factor, transforming growth factor-, IGF-II), gastrointestinal hormones (gastrin, enteroglucagon, peptide YY), and islet hormones (insulin, islet amyloid polypeptide (IAPP) and pancreatic glucagon) were determined by RIA preoperatively and after five days of treatment.No significant effects of IGF-I on other growth factors or gastrointestinal hormones were seen. A marked increase in plasma insulin postoperatively compared with the preoperative levels (42 3 vs 61 5 pM, P<0·05) was seen in the placebo group, whereas the postoperative levels in the IGF-I-treated patients remained unchanged (44 3 vs 45 4 pM). A similar pattern was observed for IAPP and cortisol concentrations. No differences in glucagon concentrations were seen.In conclusion, these results suggest that IGF-I does not influence production of other gastrointestinal hormones thought to be involved in alimentary growth or pancreatic glucagon. In contrast, IGF-I caused a marked reduction of insulin and IAPP secretion. The inhibition of -cell secretion could be direct or, alternatively, could involve an improvement in postoperative insulin resistance, perhaps by reducing serum cortisol.

show abstract

Prolonged administration of IGF peptides enhances growth of gastrointestinal tissues in normal rats

Cited by 59 publications

References 0 publications

Enteral IGF-I enhances fetal growth and gastrointestinal development in oesophageal ligated fetal sheep

Enteral IGF-I enhances fetal growth and gastrointestinal development in oesophageal ligated fetal sheep

Nutritionally Regulated Hormonal Factors in Prolonged Postnatal Growth Retardation and Its Associated Adverse Neurodevelopmental Outcome in Extreme Prematurity

Gastrointestinal growth factors and pancreatic islet hormones during postoperative IGF-I supplementation in man

Contact Info

Product

Resources

About